Could cause temporary or reversible harm; serious harm is unlikely.
Subpotent Drug and Failed Impurities/Degradation Specifications
| Brand name | RIFAMPIN |
| Generic name | RIFAMPIN |
| Active ingredient(s) | RIFAMPIN |
| Distributed by / for | Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA |
| NDC | 68180-659-06 |
| Full product label | Rifampin Capsules USP 300mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-659-06 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed to 32 Wholesale/distributor accounts who further distributed the product to 156 distribution sites. |
| Quantity | 165,60 bottles |
| Recall initiated | 2024-01-05 |
| Report date | 2024-02-07 |
| Recall completed | 2024-08-27 |
| Recall number | D-0284-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗